Abstract Body

Background: Kenya has conducted two AIDS Indicator surveys (AIS) to monitor HIV prevalence and the impact of HIV care, treatment, and prevention services in the country. The first AIS was conducted in 2007 (KAIS 2007) and the second in 2012 (KAIS 2012). Methodology: KAIS 2012 used a two-stage stratified cluster sampling design to achieve a nationally representative sample. Questionnaires were administered to persons aged 15-64 years, and blood was collected from persons aged 18 months-64 years for HIV, CD4, and viral load testing. All analyses were weighted to account for the sampling design and non-response. Estimates from KAIS 2012 were compared with estimates from KAIS 2007 to measure programmatic progress from 2007 to 2012. A z-test was used to test for differences in proportions between the two surveys. Results: Overall, 16,383 persons aged 15-64 years and 6,302 children aged 18 months-14 years were eligible in KAIS 2012. HIV prevalence was 5.6% (95% confidence interval [CI] 4.9-6.3) among persons aged 15-64 years and 0.9% (CI 0.5-1.3) among children. In 2007, HIV prevalence was 7.2% (CI 6.6-7.9) among persons aged 15-64 years. In 2012, 72% had ever been tested for HIV compared to 34% in 2007 (p<0.001). Among HIV+ persons, 47% correctly reported their HIV+ status compared to 16% in 2007 (p<0.001). The percentage of circumcised men increased from 85% in 2007 to 91% in 2012 (p<0.001), with the largest increase observed in Nyanza, from 48% in 2007 to 66% in 2012 (p<0.001). Among women who gave birth in the past five years and were diagnosed with HIV during their last pregnancy, 90% received prevention of mother-to-child transmission interventions. Among HIV+ persons aware of their infection, 89% were taking cotrimoxazole compared to 76% in 2007 (p<0.001). Overall, 59% of HIV+ persons were eligible for antiretroviral therapy (ART) based on the national ART guidelines (CD4≤350 cells/μL, tuberculosis disease, or current ART use). Among those eligible, 61% were receiving treatment, and of those, 75% were virally suppressed. Based on the 2013 World Health Organization (WHO) treatment guidelines (CD4≤500 cells/μL, tuberculosis disease, pregnant or breastfeeding women, discordant couples, or current ART use), 77% were eligible for ART, and of those, 46% were receiving ART. Conclusions: KAIS 2012 provides evidence that significant progress has been made in Kenya in the areas of HIV prevention, care, and treatment. Should Kenya adopt the new the WHO treatment guidelines, need for ART increases by nineteen percentage points and coverage decreases by fifteen percentage points, representing an additional 214,000 persons who will need to be reached. These data will be instrumental to inform implementation of strategies and new national policies for HIV control in Kenya.